Categorynews

White Paper: Safety Profile of the Analgesic Trezix™ Capsules, Containing the Mild Opioid Dihydrocodeine

April 29, 2019 Off By BusinessWire

RIDGELAND, Miss.–(BUSINESS WIRE)–Wraser Pharmaceuticals, a privately held pharmaceutical company
announces the publication of a White Paper addressing opioid safety.

Sharp rises in opioid abuse and overdose rates in the United States over
the past two decades have prompted much-needed review of prescription
rate and ease of access to controlled substances. Combatting these
alarming trends requires assessing which opioids are more addictive and
habit-forming than others and setting standards and guidelines for
prescribing that accurately reflect the relative risk of the drug.

Trezix, an oral analgesic used to manage moderate to moderately severe
pain, has a lower morphine milligram equivalent dose than stronger
opioids such as morphine, hydrocodone, and fentanyl.

In this report the writers present an overview of the safety and usage
data for Trezix and similar low dose dihydrocodeine combinations. It is
the writers carefully-considered opinion that Trezix should not be
regulated as strictly or in the same classification as opioids of
morphine-equivalent or higher strength.

“In the age of opioid concerns and disinformation, we wanted to bring
attention to alternative options for patients and the physicians who
treat them,” said Heath Wray, Wraser’ President and CEO. “WE believe
Trezix offers a pain-relieving option that is safer for the patient and
just as effective as other options for the physicians treating acute
pain.”